Navigation Links
Robert Haynes To Lead Licensing As VR Laboratories' Senior Vice President Product Introduction And Licensing
Date:11/14/2012

BONITA SPRINGS, Fla., Nov. 14, 2012 /PRNewswire-iReach/ -- VR Laboratories LLC today announced the appointment of Robert Haynes as Senior Vice President, Product Introduction and Licensing. Haynes brings more than 25 years of management and executive experience in pharmaceutical and biotechnology product development, partnering, and global commercialization.  Most recently, Haynes led the Alliance Management and New Product Planning departments at Human Genome Sciences (HGS). At HGS Haynes also led the development and global commercialization of the company's lead product - Benlysta®  - taking it from discovery through clinical development and successful commercialization around the world as the first new therapy approved for lupus in over 50 years. In addition to Benlysta Mr. Haynes has held leadership roles for numerous successful brands including Strattera®, Evista®, Axid®, Prozac®, and Ceclor®.

(Photo: http://photos.prnewswire.com/prnh/20121114/CG13570)

"Robert brings extensive experience in the pharmaceutical and biotechnology industries to VR and we look forward to his leadership in advancing our extensive pipeline internally and with partners across the globe," says Jeff Kottkamp, CEO of VR Laboratories. "As an innovative natural products company, we will benefit from his experience, developing, launching, commercializing, and partnering assets in all stages across many different therapeutic areas."

Haynes' background includes a wide variety of commercial management positions in both the pharmaceutical and biotechnology industries. This includes business development and licensing, strategic marketing, new product development, global brand and portfolio management, market research, and sales. He began his career with Eli Lilly and company in 1988 following receiving his Masters of Business Administration degree from the Owen Graduate School of Management at Vanderbilt University. In addition, he holds a Bachelors degree in Biological Science from DePauw University. 

"I look forward to continuing to develop and commercialize innovative medicines in the rapidly growing natural product industry," says Haynes. "VR Laboratories has great momentum as it looks to grow its business and expand its global presence. I'm excited to be joining VR's talented team and look forward to working with them to capitalize on their industry leading technology to build a successful fully integrated business."

About VR Laboratories

VR Laboratories is an innovative natural products company formed by industry professionals in 2010 to be the leading global formulator and producer of natural products.  VR Laboratories utilizes industry-changing proprietary technology to create, produce and market "First in Class" condition specific botanical based consumer health and wellness products, FDA-approved botanical pharmaceuticals and medicines and proprietary ingredients for medicinal and functional foods and beverages. The company utilizes a proprietary technology platform, which has fully developed more than 1,000 medicinal and functional ingredients.  VR Laboratories is headquartered in Bonita Springs, Florida.


'/>"/>
SOURCE VR Laboratories www.vr-laboratories.com
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
2. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Robert Farrell Joins Bionovos Board of Directors
5. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
6. LLSs Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
7. Sangui and SastoMed Complement Licensing Agreement in View of Increasing Sales Success
8. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
9. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
10. Aviir Diagnostic Laboratories Secures $8 Million In Funding From Silicon Valley Bank
11. Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... , ... May 18, 2016 , ... Ryan Benton was ... life expectancy in the late teens to early twenties. DMD is a relatively common ... at the age of 22, Benton’s condition was critical. He met with the founder ...
(Date:5/17/2016)... , ... May 17, 2016 , ... ... and BioSmartSA, a healthcare consultancy based in Saudi Arabia, have formed a partnership ... to healthcare providers in the Kingdom of Saudi Arabia (KSA). , The ...
(Date:5/17/2016)... 17, 2016 Strekin AG, ... Basel, Switzerland announced today the ... P38 mitogen-activated protein kinase.      (Logo: ... will build the necessary research foundation for the ... MAP Kinases play fundamental roles. Pamapimod has a ...
(Date:5/17/2016)... ... 17, 2016 , ... HOLLOWAY AMERICA, a stainless steel pressure vessel and tank ... on Thursday, May 19 in St. Louis, Missouri. The event will be held at ... a vendor showcase during the early afternoon of the event, where the company’s representatives ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):